Core Viewpoint - The company, Anglikang (002940.SZ), has received approval from the National Medical Products Administration for its drug, Doxofylline Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Doxofylline Tablets are available in dosages of 0.2g and 0.4g [1] - Doxofylline Tablets are indicated for bronchial asthma, asthmatic chronic bronchitis, and other respiratory difficulties caused by bronchospasm [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-086 一、多索茶碱片基本信息 二、药品的其他相关信息 多索茶碱片适用于支气管哮喘、喘息性慢性支气管炎及其他支气管痉挛引起 的呼吸困难。 公司于 2024 年 10 月向国家药监局递交多索茶碱片（0.2g、0.4g）补充申请， 并于同月获得受理。 1 三、对公司的影响 浙江昂利康制药股份有限公司 关于多索茶碱片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的多索茶碱片（0.2g、0.4g）《药品补 充申请批准通知书》，该药品已通过仿制药质量和疗效一致性评价。现将有关情 况公告如下： | 药品通用名称 | 多索茶碱片 | | | --- | --- | --- | | 剂型 | 片剂 | | | 注册分类 | 化学药品 | | | 规格 | 0.2g | 0.4g | | 受理号 | CYHB2450538 | CYHB2450537 | | 原药品批准文号 | 国药 ...

Group 1 - The core viewpoint of the news is that Angli康's stock price increased by 5.02%, reaching 43.55 yuan per share, with a trading volume of 1.197 billion yuan and a turnover rate of 15.44%, resulting in a total market capitalization of 8.785 billion yuan [1] - Angli康 is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main business revenue composition being: formulations 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Shenwan Lixin has a significant holding in Angli康. The Shenwan Lixin Medical Pioneer Stock A (005433) reduced its holdings by 54,900 shares in the third quarter, holding 212,100 shares, which accounts for 6.17% of the fund's net value, ranking as the fourth largest heavy stock [2] - The Shenwan Lixin Medical Pioneer Stock A (005433) has a current scale of 1.11 billion yuan and has experienced a loss of 10.27% this year, ranking 4213 out of 4216 in its category; over the past year, it has lost 17.54%, ranking 3921 out of 3922; since its inception, it has lost 51.68% [2] Group 3 - The fund manager of Shenwan Lixin Medical Pioneer Stock A (005433) is Yao Hongfu, who has been in the position for 3 years and 117 days, with the total asset scale of the fund being 1.31 billion yuan. The best fund return during his tenure is -36.17%, while the worst return is -37.16% [3]

Core Insights - The stock price of Anglikon increased by 2.07% on November 11, reaching 42.33 CNY per share, with a total market capitalization of 8.539 billion CNY [1] - Year-to-date, Anglikon’s stock has risen by 224.17%, with a recent 3.67% increase over the last five trading days [1] - For the first nine months of 2025, Anglikon reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while net profit attributable to shareholders increased by 55.59% to 77.6899 million CNY [2] Financial Performance - Anglikon has been listed on the stock market since October 23, 2018, and has a primary business focus on the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon includes 43.46% from formulations, 39.82% from raw materials, 12.44% from specialty intermediates, 3.72% from others, and 0.56% from pharmaceutical excipients [1] - Cumulative cash dividends since the A-share listing amount to 341 million CNY, with 108 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Anglikon had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which increased its holdings by 95,050 shares, and new entrants such as Huatai-PineBridge Innovation Medical Mixed A [3]

Market Overview - The chemical pharmaceutical sector increased by 1.23% on November 10, with Beijing University Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Top Performers - Beijing University Pharmaceutical (000788) closed at 6.48, up 10.02% with a trading volume of 441,200 shares and a transaction value of 278 million [1] - Anglikang (002940) closed at 41.47, up 10.00% with a trading volume of 117,000 shares and a transaction value of 479 million [1] - Xiangdi Pharmaceutical (301211) closed at 15.55, up 9.35% with a trading volume of 370,300 shares and a transaction value of 574 million [1] - Shutaishen (300204) closed at 36.69, up 7.98% with a trading volume of 703,600 shares and a transaction value of 2.572 billion [1] Underperformers - Kangzhi Pharmaceutical (300086) closed at 9.02, down 2.70% with a trading volume of 960,700 shares and a transaction value of 878 million [2] - ST Jingfeng (000908) closed at 7.45, down 2.36% with a trading volume of 196,700 shares and a transaction value of 14.7 million [2] - Haichen Pharmaceutical (300584) closed at 54.37, down 2.18% with a trading volume of 57,800 shares and a transaction value of 317 million [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 109 million from institutional investors and 137 million from speculative funds, while retail investors saw a net inflow of 247 million [2][3] - Notable net inflows from retail investors were observed in Anglikang and Xiangdi Pharmaceutical, while significant outflows were noted in Beijing University Pharmaceutical and Shutaishen [3]

Core Points - The Shanghai Composite Index is at 3998.79 points, above the six-month moving average, with a slight increase of 0.03% [1] - A total trading volume of A-shares reached 1,083.642 billion yuan today [1] - 162 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3998.79 points, reflecting a minor increase of 0.03% [1] - The total trading volume for A-shares today is 1,083.642 billion yuan [1] Stocks Exceeding Six-Month Moving Average - 162 A-shares have crossed the six-month moving average, indicating positive market sentiment [1] - Stocks with the highest deviation rates include: - Zhongyuan Qihe (8.09%) - Shunwei Co., Ltd. (4.44%) - Anglikang (4.41%) [1] Detailed Stock Data - The following stocks have notable performance metrics: - Zhongyuan Qihe: Price increased by 10.00%, with a turnover rate of 4.50% [1] - Shunwei Co., Ltd.: Price increased by 5.71%, with a turnover rate of 2.96% [1] - Anglikang: Price increased by 10.00%, with a turnover rate of 5.46% [1]

Core Points - The actual controller of Zhejiang Anglikang Pharmaceutical Co., Ltd., Mr. Lü Huaihao, has engaged in stock pledge repurchase transactions and has partially repurchased shares [1][2] - The pledged shares do not carry significant asset restructuring obligations or performance compensation liabilities [1][2] - The company confirms that Mr. Lü Huaihao has a good credit status and repayment capability, with no risk of forced liquidation or transfer of shares, ensuring no change in actual control [2] Summary by Sections - **Share Pledge and Repurchase Details** - Mr. Lü Huaihao has conducted stock pledge repurchase transactions with a repurchase date set for November 6, 2026 [1] - The pledged shares are not subject to major asset restructuring obligations [1] - **Cumulative Pledge Situation** - As of November 7, 2025, the total pledged shares by the shareholder and their concerted parties are documented, with specific details on the number of pledged and frozen shares [1] - **Risk Assessment** - The company will continue to monitor the changes in share pledges and associated risks, ensuring timely information disclosure [2]

每经头条（nbdtoutiao）——卢浮宫被盗文物竟无保险，国内48亿元艺术品保险市场也不乐观：险企称 定价太难，蛋糕看到吃不到 （记者 曾健辉） 截至发稿，昂利康市值为76亿元。 每经AI快讯，昂利康（SZ 002940，收盘价：37.7元）11月7日晚间发布公告称，公司第四届第十三次董 事会会议于2025年11月7日以通讯表决的方式召开。会议审议了《关于修订 <审计委员会年报工作规程> 的议案》等文件。 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 ...

浙江昂利康制药股份有限公司 外部信息使用人管理制度 浙江昂利康制药股份有限公司 外部信息使用人管理制度 （经公司第四届董事会第十三次会议审议通过） 第一条 为进一步加强浙江昂利康制药股份有限公司（以下简称"公司"）信 息披露工作的管理，规范外部信息使用人管理事务，确保公平信息披露，避免内幕 交易。根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《上市公司信息披露管理办法》《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》相关法律、法规和深 圳证券交易所的相关规定，结合《浙江昂利康制药股份有限公司章程》（以下简称 "《公司章程》"）及实际情况，制定本制度。 第二条 本制度的适用范围包括公司及下设各部门、分公司、全资及控股子公 司以及公司的董事、高级管理人员和其他相关人员。 第三条 本制度所指"信息"是指所有对公司股票交易价格可能产生较大影响 的信息，包括但不限于定期报告、临时报告、财务数据、正在策划或需要报批的重 大事项等。 第四条 公司对外报送信息实行分级、分类管理。公司董事会是信息对外报送 的最高管理机构，公司董事会秘书负责信息 ...

浙江昂利康制药股份有限公司 投资和融资决策管理制度 浙江昂利康制药股份有限公司 投资和融资决策管理制度 （经公司2025年第二次临时股东大会审议通过） 第一章总则 第一条 为规范浙江昂利康制药股份有限公司（下称"公司"）的投资和融资（以 下简称"投融资"）决策程序，建立系统完善的投融资决策机制，确保决策的科学、 规范、透明，有效防范各种风险，保障公司和股东的利益，根据《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》等法律法规、 规范性文件及《浙江昂利康制药股份有限公司章程》（以下简称"《公司章程》"） 等相关的规定，特制定本制度。 第二条 公司投融资决策管理的原则：决策科学民主化、行为规范程序化。 第三条 公司相关职能部门负责相应投融资事项的管理、实施、推进和监控；必 要时以项目组的形式进行投资项目的规划、论证以及年度投融资计划的编制。 第四条 公司在实施投融资事项时，应当遵循有利于公司可持续发展和全体股东 利益的原则，与实际控制人和关联人之间不存在同业竞争，并保证公司人员独立、 资产完整、财务独立；公司应具有独立经营能力，在采购、生产、销售、知识产权 等方面保持独立。 第五条 ...